News

France 2nd in the world?
Enlarge image

StudyFrance

France 2nd in the world?

24.05.2012 - France Biotech has presented its 2011 biotech survey together with France Biotech. The results are very favorable for the country.

Paris – The data of the Life Science Panorama 2010/11 survey provided by Ernst & Young claim a leading role for French biotechnology in the world. The accounting specialist has found an impressive number of 1,359 life science companies that are active in France, ranking the country 2nd in the world in terms of the number of such companies. However, the survey gives no clear criteria for the selection of the firms included. Other studies use clearly defined and internationally comparable criteria defined by the OECD. Furthermore, Ernst & Young only surveyed only about 200 companies. 103 firms responded. On this basis, Ernst & Young calculated annual revenues of €261 million in France. In comparison, a report from biotechnologie.de conform to OECD criteria found 552 biotech companies in Germany with €2.4bn in sales. As in Europe, the amount of private equity available for biotechs dropped sharply in France between 2010 and 2011 from €460m to €277m according to Ernst & Young, while the number of start ups founded balanced the number of companies liquidated (24 versus 25). However, the lack of private money could be largely compensated by state programmes such as the FSI-PME programme.  France also expanded its product pipeline. According to the report, 320 therapeutic products were in development whilst 20 were already being marketed in 2011. On top of that, diagnostic companies sold 59 in-vitro diagnostics and 21 in-vivo diagnostics. 

According to the report, the first foreign acquisitions by French companies took place in 2011. Swedish Cellartis AB was bought by Paris-based Cellectis S.A. and SC World Inc. from Japan by Vivalis SA (Nantes). In return, two French companies were acquired by foreign enterprises, namely Novagali Pharma S.A. (Évry) by Santen Pharmaceutical Co. Ltd. (Japan) and Ipsogen SA (Marseille) by Qiagen N.V. (Netherlands). 

BusinessFranceGermanySwitzerlandUK

30.07.2014 Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014